Table 1.
Clinical characteristics of patients and distribution across treatment groups
| Total of patients (n = 48) | Nivolumab + Ipilimumab (n = 12) | Pazopanib (n = 12) | Sunitinib (n = 12) | Cabozantinib (n = 12) | p-value | |
|---|---|---|---|---|---|---|
| Age at diagnosis, median (range) | 70.5 (46–83) | 64 (51–83) | 76.5 (50–83) | 64 (48–77) | 73 (46–76) | – |
| Gender | 0.03 | |||||
| Male | 36 (75%) | 8 (66.7%) | 6 (50%) | 12 (100%) | 10 (83.3%) | |
| Female | 12 (25%) | 4 (33.3%) | 6 (50%) | – | 2 (16.7%) | |
| ECOG | 0.08 | |||||
| 0 | 28 (58.3%) | 6 (50%) | 7 (58.3%) | 3 (25%) | 2 (16.7%) | |
| 1 | 18 (37.5%) | 6 (50%) | 5 (41.7%) | 9 (75%) | 8 (66.7%) | |
| 2 | 2 (4.17%) | – | – | – | 2 (16.7%) | |
| Stage at diagnosis | 0.36 | |||||
| I | 5 (10.4%) | 3 (25%) | – | 4 (33.3%) | – | |
| II | 6 (12.5%) | 2 (16.7%) | 2 (16.7%) | 1 (8.3%) | 1 (8.3%) | |
| III | 7 (14.6%) | 2 (16.7%) | 2 (16.7%) | 2 (16.7%) | 2 (16.7%) | |
| IV | 30 (62.5%) | 5 (41.7%) | 8 (66.7%) | 5 (41.7%) | 9 (75%) | |
| Nephrectomy | 0.025 | |||||
| Yes | 29 (60.4%) | 6 (50%) | 11 (91.7%) | 8 (66.7%) | 4 (33.3%) | |
| No | 19 (39.6%) | 6 (50%) | 1 (8.3%) | 4 (33.3%) | 8 (66.7%) | |
| Radiotherapy | 0.36 | |||||
| Yes | 7 (14.6%) | 2 (16.7%) | 3 (25%) | 2 (16.7%) | – | |
| No | 41 (85.4%) | 10 (83.3%) | 9 (75%) | 10 (83.3%) | 12 (100%) | |
| Metastatic sites | 0.99 | |||||
| Lung | 28 (58.3%) | 8 (66.7%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | |
| Lymph Nodes | 23 (47.9%) | 6 (50%) | 6 (50%) | 5 (41.7%) | 6 (50%) | |
| Bones | 18 (37.5%) | 5 (41.7%) | 3 (25%) | 5 (41.7%) | 4 (33.3%) | |
| Peritoneus | 8 (16.6%) | 2 (16.7%) | 1 (8.3%) | 4 (33.3%) | 1 (8.3%) | |
| Liver | 5 (10.4%) | 2 (16.7%) | 1 (8.3%) | – | 2 (16.7%) | |
| CNS | 4 (8.3%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) | |
| Adrenal | 6 (12.5%) | 2 (16.7%) | – | 3 (25%) | 1 (8.3%) | |
| Other | 19 (39.5%) | 3 (25%) | 4 (33.3%) | 7 (58.3%) | 5 (41.7%) | |